With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
Hosted on MSN6m
Can Gilead Sciences Sustain Its Growth Momentum in 2025?Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback